Shares in Solid Biosciences plunged yesterday after the FDA placed a clinical hold on the trial of its gene therapy for Duchenne muscular dystrophy (DMD) following a serious adverse reactions in one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results